FDG-PET and molecular brain imaging in the movement disorders clinic

Neurology

Volumn 79, Issue 13, 2012, Pages 1306-1307

  Bohnen, Nicolaas I ^a   Minoshima, Satoshi ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; IODOBENZAMIDE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

COHORT ANALYSIS; CORTICOBASAL DEGENERATION; DEMENTIA; EDITORIAL; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; LONGITUDINAL STUDY; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROIMAGING; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROSPECTIVE STUDY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84867545361     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826c1be1     Document Type: Editorial

References (11)

1. Hellwig S, Amtage F, Kreft A, et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012;79:1314-1322.
2. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem 1977;29:13-26.
3. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med 2012;53:59-71.
4. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-Analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27.
5. Ichise M, Kim YJ, Ballinger JR, et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopauntreated PD. Neurology 1999;52:1206-1214.
6. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912-921.
7. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149-158.
8. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using threedimensional stereotactic surface projections of fluorine-18- FDG PET. J Nucl Med 1995;36:1238-1248.
9. Burdette JH, Minoshima S, VanderBorght T, Tran DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996;198:837- 843.
10. Dukart J, Mueller K, Horstmann A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One 2011;6:e18111.
11. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247- 1258.